On November 10, Hims & Hers Health Inc. fell 8.59% in After-Hours Trading, trading near $20.8 per share, with turnover of $35.1115 million.

The move followed continued market digestion of the company’s latest quarterly earnings alongside lingering pressure from earlier FTC-related complaints and subscription billing controversies.

Recent public developments show investor focus had centered on third-quarter results and an expanded partnership with Eli Lilly to broaden access to Zepbound and Foundayo through the company’s telehealth platform. Consensus expectations ahead of the report called for revenue of $893 million, up 53.88% year over year, and EPS of about $0.06 to $0.07. Even after the Lilly partnership had briefly boosted sentiment, the stock remained under pressure after earnings, suggesting prior regulatory and customer-charging disputes were still weighing on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)